Trials & R&D · first seen yesterday, updated yesterday
Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease`
Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could…
Summary from MedCity News.